271980.KS KSC
Jeil Pharmaceutical Co.,Ltd
1W: +0.3%
1M: -12.4%
3M: -1.3%
YTD: -32.1%
1Y: -28.1%
3Y: -46.1%
5Y: -76.9%
₩10,000.00 ($7.44)
-30.00 (-0.30%)
Weekly Expected Move ±1.7%
₩9666
₩9833
₩10000
₩10167
₩10334
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$510.6B
-2.9% ▼
5Y CAGR: +4.5%
Total Liabilities
$259.5B
-15.3% ▼
5Y CAGR: +1.8%
Shareholders Equity
$211.1B
+12.2% ▲
5Y CAGR: +4.1%
Cash & Investments
$58.8B
+2.4% ▲
5Y CAGR: +54.9%
Total Debt
$93.4B
+23.4% ▲
5Y CAGR: +13.6%
Net Debt
$44.5B
+100.5% ▲
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $26.0B | $31.4B | $33.0B | $53.5B | $48.9B |
| Short-Term Investments | $2.0B | $142M | $2.7B | $4.0B | $10.0B |
| Cash & ST Investments | $28.0B | $31.6B | $35.7B | $57.5B | $58.8B |
| Net Receivables | $151.9B | $157.8B | $151.0B | $173.9B | $141.3B |
| Inventory | $102.5B | $99.2B | $109.8B | $104.4B | $104.5B |
| Other Current Assets | $0 | $0 | $20.3B | $5.0B | $5.4B |
| Total Current Assets | $284.7B | $291.6B | $317.0B | $343.0B | $311.6B |
| Property, Plant & Equip. | $125.7B | $138.4B | $137.0B | $146.2B | $147.7B |
| Goodwill & Intangibles | $3.8B | $9.4B | $4.3B | $13.4B | $15.4B |
| Long-Term Investments | $3.0B | $9.3B | $7.3B | $4.4B | $26.5B |
| Other Non-Current Assets | $7.9B | $8.0B | $21.6B | $11.3B | $2M |
| Total Non-Current Assets | $141.8B | $165.3B | $170.3B | $182.7B | $199.0B |
| Total Assets | $426.5B | $456.9B | $487.3B | $525.7B | $510.6B |
| — Liabilities — | |||||
| Accounts Payable | $153.1B | $151.6B | $144.3B | $134.6B | $89.0B |
| Short-Term Debt | $30.3B | $43.1B | $64.8B | $71.0B | $92.3B |
| Deferred Revenue | $21.4B | $1.7B | -$161M | $0 | $4.6B |
| Other Current Liabilities | $15.3B | $44.6B | $78.0B | $29.2B | $54.7B |
| Total Current Liabilities | $221.9B | $268.7B | $318.2B | $291.7B | $242.5B |
| Long-Term Debt | $9.0B | $4.0B | $0 | $0 | $0 |
| Other Non-Current Liab. | $21.6B | $23.2B | $7.7B | $12.0B | $16.0B |
| Total Non-Current Liabilities | $37.2B | $32.6B | $12.1B | $14.7B | $17.1B |
| Total Liabilities | $259.1B | $301.3B | $330.3B | $306.4B | $259.5B |
| — Equity — | |||||
| Common Stock | $7.4B | $7.4B | $7.4B | $7.4B | $7.4B |
| Retained Earnings | -$10.4B | -$20.3B | -$19.7B | -$52.9B | -$29.9B |
| Accumulated OCI | $20.8B | $20.4B | $20.4B | $32.3B | $32.1B |
| Total Stockholders Equity | $168.2B | $157.9B | $158.6B | $188.1B | $211.1B |
| Total Liabilities & Equity | $426.5B | $456.9B | $487.3B | $525.7B | $510.6B |
| — Key Metrics — | |||||
| Total Debt | $47.8B | $50.4B | $71.2B | $75.7B | $93.4B |
| Net Debt | $14.4B | $18.9B | $38.2B | $22.2B | $44.5B |
| Total Investments | $5.0B | $9.4B | $10.0B | $8.3B | $36.5B |